Methodology for and the determination of the major constituents and metabolites of the amazonian botanical medicine ayahuasca in human urine

Biomedical Chromatography

Volumn 25, Issue 9, 2011, Pages 970-984

  Mcilhenny, Ethan H ^a   Riba, Jordi ^b,c   Barbanoj, Manel J ^b   Strassman, Rick ^d,e   Barker, Steven A ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Cottonwood Research Foundation ^*  (United States)

Author keywords

Ayahuasca; Dimethyltryptamine; Harmala alkaloids; Metabolism; Urine

Indexed keywords

ALKALOIDS; BIOMOLECULES; BODY FLUIDS; CLINICAL RESEARCH; ELECTROSPRAY IONIZATION; MASS SPECTROMETRY; MEDICAL APPLICATIONS; METABOLISM; PHYSIOLOGY;

AYAHUASCUM; CLINICAL RESEARCH; DIMETHYLTRYPTAMINE; HARMALUM ALKALOID; HUMAN URINE; SAMPLE DILUTION; SELECTED REACTION MONITORING; TANDEM-MASS SPECTROMETRY; TOXICOLOGICAL RESEARCH; URINE;

METABOLITES;

DRUG METABOLITE; HARMINE; N,N DIMETHYLTRYPTAMINE;

ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOUTH AMERICA; TANDEM MASS SPECTROMETRY;

BANISTERIOPSIS CAAPI;

EID: 79959431447     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1551     Document Type: Article

References (61)

1. Andritzky W. Sociopsychotherapeutic functions of ayahuasca healing in Amazonia. Journal of Psychoactive Drugs 1989; 21: 77-89.
2. Barker SA, Monti JA and Christian ST. Metabolism of the hallucinogen N, N-dimethyltryptamine in rat brain homogenates. Biochemical Pharmacology 1980; 29: 1049-1057.
3. Barker SA, Monti JA and Christian ST. N, N-Dimethyltryptamine: an endogenous hallucinogen. International Review of Neurobiology 1981; 22: 83-110.
4. Bjornstad K, Beck O and Helander A. A multi-component LC-MS/MS method for the detection of ten plant-derived psychoactive substances in urine. Journal of Chromatography B 2009; 877; 1162-1168.
5. Callaway JC. Various alkaloid profiles in decoctions of Banisteriopsis caapi. Journal of Psychoactive Drugs 2005; 37: 1-5.
6. Callaway JC, Airaksinen MM, McKenna DJ, Brito GS and Grob CS. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology 1994; 116: 385-387.
7. Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS and Mash DC. Quantitation of N, N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. Journal of Analytical Toxicology 1996; 20: 492-497.
8. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Andrade EO and Mash DC. Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 1999; 65: 243-256.
9. Callaway JC, Brito GS and Neves ES. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. Journal of Psychoactive Drugs 2005; 37: 145-150.
10. Chambers E, Wagrowski-Diehl DM, Lu Z and Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. Journal of Chromatography B 2007; 852: 22-34.
11. Cohen I and Vogel WH. Determination and physiological disposition of dimethyltryptamine and diethyltryptamine in rat brain, liver and plasma. Biochemical Pharmacology 1972; 21: 1214-1216.
12. Fish MS, Johnson NM, Lawrence EP and Horning EC. Oxidative N-dealkylation. Biochemica et Biophysica Acta 1955; 18: 564-565.
13. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB and Ruoho AE. The hallucinogen N, N-dimethyltryptamine is an endogenous Sigma-1 receptor regulator. Science 2009; 323: 934-937.
14. Food and Drug Administration. Guidance for industry on bioanalytical method validation. Federal Register 2001; 66: 28526.
15. Frison G, Favretto D, Zancanaro F, Fazzin G and Ferrara SD. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Science International 2008; 179: e37-e43.
16. Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 2007; 102; 24-34.
17. Gambelunghe G, Aroni K, Rossi R, Moretti L and Bacci M. Identification of N, N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage. Biomedical Chromatography 2008; 22: 1056-1059.
18. Gillin JC, Kaplan J, Stillman R and Wyatt RJ. The psychedelic model of schizophrenia: the case of N, N-dimethyltryptamine. American Journal of Psychiatry 1976; 133: 203-208.
19. Hallikainen T, Saito HM, Lachman J, Volavka T, Pohjalainen OP, Ryynanen J, Kauhanenm J, Syvalahti E, Hietala J and Tiihonen J. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Molecular Psychiatry 1999; 4: 385-388.
20. Hashimoto Y and Kawanishi K. New organic bases from Amazonian Banisteriopsis caapi. Phytochemistry 1975; 14: 1633-1635.
21. Hashimoto Y and Kawanishi K. New alkaloids from Banisteriopsis caapi. Phytochemistry 1976; 15: 1559-1560.
22. Hryhorczuk LM, Rainey JM, Frohman C and Novak E. A new metabolic pathway for N, N-dimethyltryptamine. Biological Psychiatry 1986; 21: 84-93.
23. Kaplan J, Mandel LR, Stillman R, Walker RW, VandenHeuvel WJA, Gillin JC and Wyatt RJ. Blood and urine levels of N, N-dimethyltryptamine following administration of psychoactive doses to human subjects. Psychopharmacologia 1974; 38: 239-245.
24. Kawanishi K, Saiki K, Tomita H, Tachibana Y, Farnsworth NR and Bohlke M. Chemical components of the Brazilian shamanistic drink 'Ayahuasca.' Advances in Mass Spectrometry 1998; 14: D053560/1.
25. Kim H, Sablin SO and Ramsay RR. Inhibition of monoamine oxidase A by beta-carboline derivatives. Archives of Biochemistry and Biophysics 1997; 337: 137-142.
26. Mabit J, Giove R and Vega J. In Yearbook of Cross-Cultural Medicine and Psychotherapy, Winkelman M and Andritzky W (eds). VMB Press: Berlin, 1996; 257.
27. Mandel LR, Prasad R, Lopez-Ramos B and Walker RW. The biosynthesis of dimethyltryptamine in vivo. Research Communications in Chemical Pathology and Pharmacology 1977; 16: 47-58.
28. Mantere T, Tupala E, Hall H, Sarkioja T, Rasanen P, Bergstorm K, Callaway JC and Tiihonen J. Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study. American Journal of Psychiatry 2002; 159: 599-606.
29. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75; 3019-3030.
30. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. Journal of Chromatography B 2006; 830: 293-300.
31. McIlhenny EH, Pipkin KE, Standish LJ, Wechkin HA, Strassman RJ and Barker SA. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. Journal of Chromatography A 2009; 1216: 8960-8968.
32. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology and Therapeutics 2004; 102: 111-129.
33. McKenna DJ and Towers GHN. Biochemistry and pharmacology of tryptamines and beta-carbolines: a minireview. Journal of Psychoactive Drugs 1984; 16: 347-358.
34. McKenna DJ, Towers GHN and Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. Journal of Ethnopharmacology 1984; 10: 195-223.
35. McKenna DJ, Luna LE and Towers GHN. In Ethnobotany: Evolution of a Discipline, von Reis S, Schultes RE (eds). Dioscorides Press: Portland, OR, 1995; 349.
36. Moura DJ, Richter MF, Boeira JB, Henriques JAP and Saffi J. Antioxidant properties of β-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 2007; 22: 293-302.
37. Ott J. Pharmahuasca: human pharmacology of oral DMT plus harmine. Journal of Psychoactive Drugs 1999; 31: 171-177.
38. Pires APS, De Oliveira CDR, Moura S, Dorr FA, Silva WAE and Yonamine M. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Phytochemical Analysis 2009; 20: 149-153.
39. Riba J. Human pharmacology of ayahuasca. Doctoral Thesis, Universitat Autonoma de Barcelona, 2003;
40. Riba J and Barbanoj MJ. Bringing ayahuasca to the clinical research laboratory. Journal of Psychoactive Drugs 2005; 37: 219-230.
41. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC and Barbanoj MJ. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berlin) 2001; 154: 85-95.
42. Riba J, Valle M, Urbano G, Yritia M, Morte A and Barbanoj MJ. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 73-83.
43. Rivier L and Lindgren JE. 'Ayahuasca, ' the South American hallucinogenic drink: an ethnobotanical and chemical investigation. Economic Botany 1972; 26: 101-129.
44. Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V and Cruz APM. Effects of ayhuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology 2007; 112: 507-513.
45. Schultes RE. The identity of the maipighiaceous narcotics of South America. Botanical Museum Leaflets, Harvard University 1957; 18: 1-56.
46. Schultes RE and Hofmann A. The Botany and Chemistry of Hallucinogens. Charles C. Thomas: Springfield, IL, 1980.
47. Sitaram BR and McLeod WR. Observations on the metabolism of the psychotomimetic indolealkylamines: Implications for future clinical studies. Biological Psychiatry 1990; 28: 841-848.
48. Sitaram BR, Lockett L, Blackman GL and McLeod WR. Urinary excretion of 5-methoxy-N, N-dimethyltryptamine, N, N-dimethyltryptamine and their N-oxides in the rat. Biochemical Pharmacology 1987a; 36: 2235-237.
49. Sitaram BR, Lockett L, Talomsin R, Blackman GL and McLeod WR. In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N, N-dimethyltryptamine in the rat. Biochemical Pharmacology 1987b; 36: 1509-1512.
50. Sitaram BR, Talomsin R, Blackman GL and McLeod WR. Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography. Biochemical Pharmacology 1987c; 36: 1503-1508.
51. Slotkin TA, DiStefano V and Au WYW. Blood levels and urinary excretion of harmine and its metabolites in man and rats. Journal of Pharmacology and Experimental Therapeutics 1970; 173: 26-30.
52. Strassman RJ, Qualls CR, Uhlenhuth EH and Kellner R. Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results. Archives of General Psychiatry 1994; 51: 98-108.
53. Su T-P, Hayashi T and Vaupel DP. When the endogenous hallucinogenic trace amine N, N-dimethyltryptamine meets the Sigma-1 receptor. Science Signaling 2009; 2: 1-4.
54. Suzuki O, Katsumata Y and Oya M. Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochemical Pharmacology 1981; 30: 1353-1358.
55. Szara S and Axelrod J. Hydroxylation and N-demethylation of N, N-dimethyltryptamine. Experientia 1959; 15: 216-217.
56. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometery. Clinical Biochemistry 2005; 38: 328-334.
57. Tiihonen J, Kiukka JT, Bergstorm KA, Karhu J, Viinamaki H, Lehtonen J, Hallikainen T, Yang J and Hakola P. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behavior. European Journal of Nuclear Medicine 1997; 24: 1253-1260.
58. Tweedie DJ and Burke MD. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites. Drug Metabolism and Disposition 1987; 15: 74-81.
59. Yritia M, Riba J, Ortuno J, Ramirez A, Castillo A, Alfaro Y, De La Torre R and Barbanoj MJ. Determination of N, N-dimethyltryptamine and beta carboline alkaloids in human plasma following oral administration of Ayahuasca. Journal of Chromatography B 2002; 779: 271-281.
60. Yu A. Indolealkylamines: biotransformations and potential drug-drug interactions. American Association of Pharmaceutical Scientists Journal 2008; 10: 242-253.
61. Yu A, Idle JR, Krausz KW, Küpfer A and Gonzalez FJ. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. Journal of Pharmacology and Experimental Therapeutics 2003; 305: 315-322.